Literature DB >> 22349490

Diabetes: Should we use fibrates in patients with diabetes and mild CKD?

David Lewis, Christoph Wanner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22349490     DOI: 10.1038/nrneph.2012.37

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

Review 1.  Chronic kidney disease.

Authors:  Andrew S Levey; Josef Coresh
Journal:  Lancet       Date:  2011-08-15       Impact factor: 79.321

2.  Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.

Authors:  T M E Davis; R Ting; J D Best; M W Donoghoe; P L Drury; D R Sullivan; A J Jenkins; R L O'Connell; M J Whiting; P P Glasziou; R J Simes; Y A Kesäniemi; V J Gebski; R S Scott; A C Keech
Journal:  Diabetologia       Date:  2010-11-04       Impact factor: 10.122

3.  Effects of combination lipid therapy in type 2 diabetes mellitus.

Authors:  Henry N Ginsberg; Marshall B Elam; Laura C Lovato; John R Crouse; Lawrence A Leiter; Peter Linz; William T Friedewald; John B Buse; Hertzel C Gerstein; Jeffrey Probstfield; Richard H Grimm; Faramarz Ismail-Beigi; J Thomas Bigger; David C Goff; William C Cushman; Denise G Simons-Morton; Robert P Byington
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

Review 4.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

Authors:  Min Jun; Celine Foote; Jicheng Lv; Bruce Neal; Anushka Patel; Stephen J Nicholls; Diederick E Grobbee; Alan Cass; John Chalmers; Vlado Perkovic
Journal:  Lancet       Date:  2010-05-10       Impact factor: 79.321

5.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Authors:  A Keech; R J Simes; P Barter; J Best; R Scott; M R Taskinen; P Forder; A Pillai; T Davis; P Glasziou; P Drury; Y A Kesäniemi; D Sullivan; D Hunt; P Colman; M d'Emden; M Whiting; C Ehnholm; M Laakso
Journal:  Lancet       Date:  2005-11-26       Impact factor: 79.321

6.  Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people.

Authors:  Jean-Claude Ansquer; R Neil Dalton; Elisabeth Caussé; Dominique Crimet; Karine Le Malicot; Christelle Foucher
Journal:  Am J Kidney Dis       Date:  2008-04-02       Impact factor: 8.860

7.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

8.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Authors:  Colin Baigent; Martin J Landray; Christina Reith; Jonathan Emberson; David C Wheeler; Charles Tomson; Christoph Wanner; Vera Krane; Alan Cass; Jonathan Craig; Bruce Neal; Lixin Jiang; Lai Seong Hooi; Adeera Levin; Lawrence Agodoa; Mike Gaziano; Bertram Kasiske; Robert Walker; Ziad A Massy; Bo Feldt-Rasmussen; Udom Krairittichai; Vuddidhej Ophascharoensuk; Bengt Fellström; Hallvard Holdaas; Vladimir Tesar; Andrzej Wiecek; Diederick Grobbee; Dick de Zeeuw; Carola Grönhagen-Riska; Tanaji Dasgupta; David Lewis; William Herrington; Marion Mafham; William Majoni; Karl Wallendszus; Richard Grimm; Terje Pedersen; Jonathan Tobert; Jane Armitage; Alex Baxter; Christopher Bray; Yiping Chen; Zhengming Chen; Michael Hill; Carol Knott; Sarah Parish; David Simpson; Peter Sleight; Alan Young; Rory Collins
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321

9.  Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.

Authors:  Ru-Dee Ting; Anthony C Keech; Paul L Drury; Mark W Donoghoe; John Hedley; Alicia J Jenkins; Timothy M E Davis; Seppo Lehto; David Celermajer; R John Simes; Kushwin Rajamani; Kim Stanton
Journal:  Diabetes Care       Date:  2011-12-30       Impact factor: 19.112

10.  The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481].

Authors: 
Journal:  Cardiovasc Diabetol       Date:  2004-12-01       Impact factor: 9.951

  10 in total
  1 in total

1.  Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context.

Authors:  Laure Monteillet; Monika Gjorgjieva; Marine Silva; Vincent Verzieux; Linda Imikirene; Adeline Duchampt; Hervé Guillou; Gilles Mithieux; Fabienne Rajas
Journal:  Mol Metab       Date:  2018-08-01       Impact factor: 7.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.